Non-Communicable Diseases Group, Translational Health Science and Technology Institute (THSTI), 121001, Faridabad, India.
Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India.
Oxid Med Cell Longev. 2020 Jun 11;2020:7856318. doi: 10.1155/2020/7856318. eCollection 2020.
Allylmethylsulfide (AMS) is a novel sulfur metabolite found in the garlic-fed serum of humans and animals. In the present study, we have observed that AMS is safe on chronic administration and has a potential antihypertrophic effect. Chronic administration of AMS for 30 days did not cause any significant differences in the body weight, electrocardiogram, food intake, serum biochemical parameters, and histopathology of vital organs. Single-dose pharmacokinetics of AMS suggests that AMS is rapidly metabolized into Allylmethylsulfoxide (AMSO) and Allylmethylsulfone (AMSO). To evaluate the efficacy of AMS, cardiac hypertrophy was induced by subcutaneous implantation of ALZET® osmotic minipump containing isoproterenol (~5 mg/kg/day), cotreated with AMS (25 and 50 mg/kg/day) and enalapril (10 mg/kg/day) for 2 weeks. AMS and enalapril significantly reduced cardiac hypertrophy as studied by the heart weight to body weight ratio and mRNA expression of fetal genes (ANP and -MHC). We have observed that TBARS, a parameter of lipid peroxidation, was reduced and the antioxidant enzymes (glutathione, catalase, and superoxide dismutase) were improved in the AMS and enalapril-cotreated hypertrophic hearts. The extracellular matrix (ECM) components such as matrix metalloproteinases (MMP2 and MMP9) were significantly upregulated in the diseased hearts; however, with the AMS and enalapril, it was preserved. Similarly, caspases 3, 7, and 9 were upregulated in hypertrophic hearts, and with the AMS and enalapril treatment, they were reduced. Further to corroborate this finding with data, we have checked the nuclear expression of caspase 3/7 in the H9c2 cells treated with isoproterenol and observed that AMS cotreatment reduced it significantly. Histopathological investigation of myocardium suggests AMS and enalapril treatment reduced fibrosis in hypertrophied hearts. Based on our experimental results, we conclude that AMS, an active metabolite of garlic, could reduce isoproterenol-induced cardiac hypertrophy by reducing oxidative stress, apoptosis, and stabilizing ECM components.
烯丙基甲基硫醚 (AMS) 是一种在大蒜喂养的人类和动物血清中发现的新型硫代谢物。在本研究中,我们观察到 AMS 在慢性给药时是安全的,并且具有潜在的抗肥厚作用。连续 30 天给予 AMS 不会导致体重、心电图、食物摄入、血清生化参数和重要器官的组织病理学发生任何显著变化。AMS 的单次剂量药代动力学表明,AMS 迅速代谢为烯丙基甲基亚砜 (AMSO) 和烯丙基甲基砜 (AMSO)。为了评估 AMS 的疗效,通过皮下植入含有异丙肾上腺素 (~5mg/kg/天) 的 ALZET®渗透微型泵诱导心脏肥厚,并用 AMS(25 和 50mg/kg/天) 和依那普利 (10mg/kg/天) 共同处理 2 周。AMS 和依那普利显著降低了心脏重量与体重比和胎儿基因 (ANP 和-β-MHC) 的 mRNA 表达所研究的心脏肥厚。我们观察到丙二醛 (TBARS),一种脂质过氧化的参数,在 AMS 和依那普利共同处理的肥厚心脏中降低,抗氧化酶 (谷胱甘肽、过氧化氢酶和超氧化物歧化酶) 得到改善。细胞外基质 (ECM) 成分,如基质金属蛋白酶 (MMP2 和 MMP9),在患病心脏中显著上调;然而,在 AMS 和依那普利的作用下,它被保留了下来。同样,caspase 3、7 和 9 在肥厚心脏中上调,而在 AMS 和依那普利治疗后,它们减少了。为了进一步用数据证实这一发现,我们检查了用异丙肾上腺素处理的 H9c2 细胞中 caspase 3/7 的核表达,观察到 AMS 共同处理显著降低了它。心肌组织学研究表明,AMS 和依那普利治疗减少了肥厚心脏中的纤维化。基于我们的实验结果,我们得出结论,大蒜的活性代谢物 AMS 可以通过降低氧化应激、细胞凋亡和稳定 ECM 成分来减少异丙肾上腺素诱导的心脏肥厚。